Tags

Type your tag names separated by a space and hit enter

The rise of a new GABA pharmacology.
Neuropharmacology. 2011 Jun; 60(7-8):1042-9.N

Abstract

Key developments in GABA pharmacology over the last 30 years are reviewed with special reference to the advances pioneered by Erminio Costa. His passion for innovative science, and his quest for novel therapies for psychiatric disorders are particularly apparent in his fundamental contributions to the field of GABA research, with a focus on anxiety disorders and schizophrenia. He was a cofounder of the GABAergic mechanism of action of benzodiazepines. He envisaged partial agonists as novel anxiolytics. He identified DBI (diazepam binding inhibitor) as endogenous agonist of neurosteroidogenesis with multiple CNS effects and he pointed to the developmental origin of GABAergic dysfunctions in schizophrenia through his discovery of a reelin deficit, all this in collaboration with Sandro Guidotti. Today, the GABA pharmacology comprises selective hypnotics, non-sedative anxiolytics, memory enhancers and powerful analgesics. This article is part of a Special Issue entitled 'Trends in neuropharmacology: in memory of Erminio Costa'.

Authors+Show Affiliations

Institute of Pharmacology, University of Zurich and Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH) Zurich, Winterthurerstr. 190, CH-8057 Zurich, Switzerland. mohler@pharma.unizh.ch

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

21035473

Citation

Möhler, Hanns. "The Rise of a New GABA Pharmacology." Neuropharmacology, vol. 60, no. 7-8, 2011, pp. 1042-9.
Möhler H. The rise of a new GABA pharmacology. Neuropharmacology. 2011;60(7-8):1042-9.
Möhler, H. (2011). The rise of a new GABA pharmacology. Neuropharmacology, 60(7-8), 1042-9. https://doi.org/10.1016/j.neuropharm.2010.10.020
Möhler H. The Rise of a New GABA Pharmacology. Neuropharmacology. 2011;60(7-8):1042-9. PubMed PMID: 21035473.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The rise of a new GABA pharmacology. A1 - Möhler,Hanns, Y1 - 2010/10/28/ PY - 2010/09/06/received PY - 2010/10/13/revised PY - 2010/10/21/accepted PY - 2010/11/2/entrez PY - 2010/11/3/pubmed PY - 2012/1/19/medline SP - 1042 EP - 9 JF - Neuropharmacology JO - Neuropharmacology VL - 60 IS - 7-8 N2 - Key developments in GABA pharmacology over the last 30 years are reviewed with special reference to the advances pioneered by Erminio Costa. His passion for innovative science, and his quest for novel therapies for psychiatric disorders are particularly apparent in his fundamental contributions to the field of GABA research, with a focus on anxiety disorders and schizophrenia. He was a cofounder of the GABAergic mechanism of action of benzodiazepines. He envisaged partial agonists as novel anxiolytics. He identified DBI (diazepam binding inhibitor) as endogenous agonist of neurosteroidogenesis with multiple CNS effects and he pointed to the developmental origin of GABAergic dysfunctions in schizophrenia through his discovery of a reelin deficit, all this in collaboration with Sandro Guidotti. Today, the GABA pharmacology comprises selective hypnotics, non-sedative anxiolytics, memory enhancers and powerful analgesics. This article is part of a Special Issue entitled 'Trends in neuropharmacology: in memory of Erminio Costa'. SN - 1873-7064 UR - https://www.unboundmedicine.com/medline/citation/21035473/The_rise_of_a_new_GABA_pharmacology_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0028-3908(10)00290-X DB - PRIME DP - Unbound Medicine ER -